Stock Market Reviews

ENTA (Enanta Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on ENTA (Enanta Pharmaceuticals, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Enanta Pharmaceuticals Insider Ups Holding During Year
  Looking at Enanta Pharmaceuticals, Inc.'s ( NASDAQ:ENTA ) insider transactions over the last year, we can see that...
  Jan 1, 2026 - $ENTA
• Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains?
  Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
  Dec 26, 2025 - $ENTA
• Enanta Pharmaceuticals (ENTA) Surges 5.9%: Is This an Indication of Further Gains?
  Enanta Pharmaceuticals (ENTA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
  Dec 22, 2025 - $ENTA
• Wall Street Analysts Believe Enanta Pharmaceuticals (ENTA) Could Rally 44.85%: Here's is How to Trade
  The consensus price target hints at a 44.9% upside potential for Enanta Pharmaceuticals (ENTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
  Nov 21, 2025 - $ENTA
• Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
  WATERTOWN, Mass., November 17, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal fourth quarter and year-ended September 30, 2025.
  Nov 17, 2025 - $ENTA
• Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has caught the attention of institutional investors who hold a sizeable 44% stake
  Key Insights Institutions' substantial holdings in Enanta Pharmaceuticals implies that they have significant influence...
  Nov 4, 2025 - $ENTA
• Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
  WATERTOWN, Mass., November 04, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in the following investor conferences in November and December.
  Nov 4, 2025 - $ENTA
• Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
  WATERTOWN, Mass., October 20, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that new data for zelicapavir, its oral, once-daily, N-protein inhibitor, and EDP-323, its oral, once-daily L-protein inhibitor, both in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek™ 2025 being held October 19 – 22,
  Oct 20, 2025 - $ENTA
• Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
  WATERTOWN, Mass., October 07, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for zelicapavir, its oral, once-daily, N-protein inhibitor, and EDP-323, it’s oral, once-daily L-protein inhibitor, both in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek™ 2025 being held October 19 - 22, 20
  Oct 7, 2025 - $ENTA
• Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
  WATERTOWN, Mass., October 02, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that it has closed its previously announced underwritten public offering of 7,475,000 shares of its common stock, which includes 975,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $10.0
  Oct 2, 2025 - $ENTA